Skip to main content

Table 1 Characteristics of 122 patients with rheumatic diseases and 366 cancer-matched controls without RD

From: Survival rates of cancer patients with and without rheumatic disease: a retrospective cohort analysis

  RA (n = 80) SLE (n = 13) SSc (n = 13) DM/PM (n = 16) All RD (n = 122) Non-RD (n = 366)
Female, n (%) 59 (73.8) 13 (100.0) 10 (76.9) 6 (37.5) 88 (72.1) 264 (72.1)
Age at RD dx, yrs, 54.7 ± 12.8 42.4 ± 12.9 45.6 ± 16.1 58.2 ± 9.9 52.4 ± 13.5 N/A
Age at cancer dx, yrs, 60.2 ± 11.3 52.2 ± 9.7 54.2 ± 13.9 59.7 ± 9.3 58.7 ± 11.5 58.6 ± 11.6
Follow-up duration, yrs 14.4 ± 12.0 17.3 ± 10.2 10.7 ± 7.1 13.0 ± 11.2 12.8 ± 9.7 12.8 ± 9.7
Cancer type, n (%)       
Stomach 18 (22.2) 4 (30.8) 2 (15.4) 4 (25.0) 28 (23.0) 83 (22.7)
Colon 16 (20.0) 3 (23.1) 1 (7.7) 3 (18.8) 23 (18.9) 69 (18.9)
Lung 28 (35.0) 0 (0) 10 (76.9) 6 (37.5) 44 (36.1) 133 (36.3)
Breast 18 (22.5) 6 (46.2) 0 (0.0) 3 (18.8) 27 (22.1) 81 (22.1)
Interstitial lung disease, n (%) 6 (7.5) 1 (7.7) 7 (53.8) 3 (18.8) 17 (13.9) 3 (0.8)
Treatment of RD, n (%)       
Methotrexate 53 (66.3) 1 (7.7) 0 (0) 5 (31.3) 59 (48.4) N/A
Other DMARDs 57 (71.3) 6 (46.2) 2 (15.4) 6 (37.5) 71 (58.2) N/A
Corticosteroids 48 (60.0) 7 (58.3) 4 (30.8) 13 (81.3) 72 (59.0) N/A
TNF inhibitors 4 (5.0) 0 (0) 0 (0) 0 (0) 4 (3.3) N/A
Othersa 5 (6.3) 4 (30.8) 2 (15.4) 4 (25.0) 15(12.3) N/A
  1. Data are expressed as the mean ± SD or as number (%)
  2. Dx diagnosis, DMARD disease modifying antirheumatic drug, DM/PM dermatomyositis/polymyositis, N number, N/A not applicable, RA rheumatoid arthritis, RD rheumatic disease, SLE systemic lupus erythematosus, SSc systemic sclerosis, TNF tumor necrosis factor, Yrs years
  3. aOthers include tocilizumab, rituximab, abatacept, bucillamine, and cyclosporine